Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T56365
|
||||
Former ID |
TTDC00135
|
||||
Target Name |
B-lymphocyte antigen CD19
|
||||
Gene Name |
CD19
|
||||
Synonyms |
B-lymphocyte surface antigen B4; Differentiation antigen CD19; Leu-12; CD19
|
||||
Target Type |
Clinical Trial
|
||||
Disease | Autoimmune diabetes [ICD10: E08-E13] | ||||
Acute lymphoblastic leukemia [ICD9: 204.0, 556; ICD10: C91.0] | |||||
B-cell lymphoma [ICD9: 202.8; ICD10: C85.1] | |||||
Chronic lymphocytic leukaemia [ICD10: C91] | |||||
Diffuse large B-cell lymphoma [ICD9: 200; ICD10: C83.3] | |||||
Hematologic malignancies [ICD9: 200-209; ICD10: C81-C86] | |||||
Lymphoma; Chronic lymphocytic leukemia; Multiple myeloma [ICD9: 202.8, 203.0, 204.1, 208.9; ICD10: C81-C86, C90, C91-C95, C91.1] | |||||
Leukemia [ICD9: 208.9; ICD10: C90-C95] | |||||
Non-hodgkin's lymphoma [ICD10: C85] | |||||
Rheumatoid arthritis [ICD9: 710-719, 714; ICD10: M05-M06] | |||||
Scleroderma [ICD9: 701.0710.1; ICD10: L94.0-L94.1, M34] | |||||
Function |
Assembles with the antigen receptor of B-lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation.
|
||||
BioChemical Class |
Immunoglobulin
|
||||
Target Validation |
T56365
|
||||
UniProt ID | |||||
Sequence |
MPPPRLLFFLLFLTPMEVRPEEPLVVKVEEGDNAVLQCLKGTSDGPTQQLTWSRESPLKP
FLKLSLGLPGLGIHMRPLAIWLFIFNVSQQMGGFYLCQPGPPSEKAWQPGWTVNVEGSGE LFRWNVSDLGGLGCGLKNRSSEGPSSPSGKLMSPKLYVWAKDRPEIWEGEPPCLPPRDSL NQSLSQDLTMAPGSTLWLSCGVPPDSVSRGPLSWTHVHPKGPKSLLSLELKDDRPARDMW VMETGLLLPRATAQDAGKYYCHRGNLTMSFHLEITARPVLWHWLLRTGGWKVSAVTLAYL IFCLCSLVGILHLQRALVLRRKRKRMTDPTRRFFKVTPPPGSGPQNQYGNVLSLPTPTSG LGRAQRWAAGLGGTAPSYGNPSSDVQADGALGSRSPPGVGPEEEEGEGYEEPDSEEDSEF YENDSNLGQDQLSQDGSGYENPEDEPLGPEDEDSFSNAESYENEDEELTQPVARTMDFLS PHGSAWDPSREATSLGSQSYEDMRGILYAAPQLRSIRGQPGPNHEEDADSYENMDNPDGP DPAWGGGGRMGTWSTR |
||||
Drugs and Mode of Action | |||||
Drug(s) | Blinatumomab | Drug Info | Approved | Acute lymphoblastic leukemia | [889388], [889412] |
CTL019 | Drug Info | Phase 2 | Chronic lymphocytic leukaemia | [525190] | |
JCAR015 | Drug Info | Phase 2 | B-cell lymphoma | [525305] | |
MDX-1342 | Drug Info | Phase 2 | Leukemia | [524501] | |
MOR-208 | Drug Info | Phase 2 | Autoimmune diabetes | [524052] | |
SAR-3419 | Drug Info | Phase 2 | Non-hodgkin's lymphoma | [532514] | |
Xmab 5871 | Drug Info | Phase 2 | Autoimmune diabetes | [549317] | |
JCAR014 | Drug Info | Phase 1/2 | Non-hodgkin's lymphoma | [549571] | |
JCAR017 | Drug Info | Phase 1/2 | Leukemia | [549572] | |
KTE-C19 CAR | Drug Info | Phase 1/2 | Diffuse large B-cell lymphoma | [549522] | |
Xmab5871 | Drug Info | Phase 1/2 | Rheumatoid arthritis | [889425] | |
AFM11 | Drug Info | Phase 1 | Non-hodgkin's lymphoma | [524703] | |
Combotox | Drug Info | Phase 1 | Leukemia | [548715] | |
MEDI-551 | Drug Info | Phase 1 | Lymphoma; Chronic lymphocytic leukemia; Multiple myeloma | [542906], [551134] | |
MEDl-551 | Drug Info | Phase 1 | Scleroderma | [531971] | |
SGN-19A | Drug Info | Preclinical | Hematologic malignancies | [551669] | |
Modulator | AFM11 | Drug Info | [889442] | ||
Anti-CD22/CD19 mab-toxin conjugate | Drug Info | [525761] | |||
Blinatumomab | Drug Info | [533123] | |||
Combotox | Drug Info | ||||
CTL019 | Drug Info | [551967] | |||
JCAR014 | Drug Info | [551860] | |||
JCAR015 | Drug Info | [551860] | |||
JCAR017 | Drug Info | [551860] | |||
Xmab 5871 | Drug Info | ||||
Xmab5871 | Drug Info | [889442] | |||
Inhibitor | KTE-C19 CAR | Drug Info | [549913] | ||
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
TEP | EXP Info | ||||
Pathways | |||||
KEGG Pathway | PI3K-Akt signaling pathway | ||||
Hematopoietic cell lineage | |||||
B cell receptor signaling pathway | |||||
Epstein-Barr virus infection | |||||
Primary immunodeficiency | |||||
NetPath Pathway | IL-7 Signaling Pathway | ||||
PANTHER Pathway | B cell activation | ||||
Pathway Interaction Database | BCR signaling pathway | ||||
Reactome | PIP3 activates AKT signaling | ||||
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | |||||
Constitutive Signaling by Aberrant PI3K in Cancer | |||||
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | |||||
WikiPathways | Human Complement System | ||||
Signaling by the B Cell Receptor (BCR) | |||||
PIP3 activates AKT signaling | |||||
B Cell Receptor Signaling Pathway | |||||
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | |||||
References | |||||
Ref 524052 | ClinicalTrials.gov (NCT01685008) Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin?? Lymphoma (NHL). U.S. National Institutes of Health. | ||||
Ref 524501 | ClinicalTrials.gov (NCT01974479) Pilot Study of Redirected Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia. U.S. National Institutes of Health. | ||||
Ref 524703 | ClinicalTrials.gov (NCT02106091) Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL or B-precursor ALL. U.S. National Institutes of Health. | ||||
Ref 525190 | ClinicalTrials.gov (NCT02445248) Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients. U.S. National Institutes of Health. | ||||
Ref 525305 | ClinicalTrials.gov (NCT02535364) Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL). | ||||
Ref 532514 | A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res. 2014 Jan 1;20(1):213-20. | ||||
Ref 542906 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7992). | ||||
Ref 548715 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027936) | ||||
Ref 549317 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035125) | ||||
Ref 549522 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800039436) | ||||
Ref 549571 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800041075) | ||||
Ref 549572 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800041076) | ||||
Ref 889388 | ClinicalTrials.gov (NCT02013167) Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) | ||||
Ref 525761 | Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro. Leukemia. 2000 May;14(5):853-8. | ||||
Ref 530298 | A nonfucosylated human antibody to CD19 with potent B-cell depletive activity for therapy of B-cell malignancies. Cancer Immunol Immunother. 2010 Feb;59(2):257-65. | ||||
Ref 532514 | A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res. 2014 Jan 1;20(1):213-20. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.